TY - JOUR
T1 - Risk factors for serious adverse events associated with multiband mucosectomy in Barrett's esophagus
T2 - an international multicenter analysis of 3827 endoscopic resection procedures
AU - Belghazi, Kamar
AU - Marcon, Norman
AU - Teshima, Christopher
AU - Wang, Kenneth K.
AU - Milano, Reza V.
AU - Mostafavi, Nahid
AU - Wallace, Michael B.
AU - Kandel, Pujan
AU - Mejía Pérez, Lady Katherine
AU - Bourke, Michael J.
AU - Bahin, Farzan
AU - Everson, Martin A.
AU - Haidry, Rehan
AU - Ginsberg, Gregory G.
AU - Ma, Gene K.
AU - Koch, Arjun D.
AU - Ragunath, Krish
AU - Ortiz-Fernandez-Sordo, Jacobo
AU - di Pietro, Massimiliano
AU - Seewald, Stefan
AU - Weusten, Bas L.
AU - Schoon, Erik J.
AU - Bisschops, Raf
AU - Bergman, Jacques J.
AU - Pouw, Roos E.
N1 - Funding Information:
DISCLOSURE: Dr Teshima received research support from Medtronic and Vantage Endoscopy. Dr Wang has consulted for Boston Scientific and undertaken research for Interscope and Fujinon. Dr Wallace has received research grants from Fujifilm , Medtronic , ChiroChem , Olympus , and Boston Scientific , has been a consultant for Ninepoint on behalf of Mayo Clinic and a general consultant for Cosmo Pharmaceuticals. Dr Haidry has undertaken research for Cook Medical, Pentax Europe, Covidien/Medtronic, Beamline Technologies, and C2 Therapeutics. Dr Koch has undertaken research for Cook medical and Interscope and has received speaker and consultancy fees from ErbeElektromedizin. Dr Ragunath has received educational and research grants from Cook Medical , consultancy fees from Olympus, consultancy fees and educational grants from Boston Scientific, and educational and research grants from Pentax . Dr Weusten has received financial support for research and speaker fees from Pentax Medical. Dr Schoon has received speaker and consultancy fees from Medtronic, Boston Scientific, and Olympus, and financial support for research from Fujifilm. Dr Bisschops has received speaker fees from Medtronic, Pentax, and Fujifilm, consultancy fees from Medtronic, Boston Scientific, Pentax, and Fujifilm, and financial support for research from Cook Medical, Medtronic, Pentax, and Fujifilm. Dr Bergman has received financial support for research from Covidien/Medtronic, Olympus Endoscopy, Cook Medical, Boston Scientific, Erbe Medical, C2 Therapeutic, and Ninepoint Medical, and consultancy fees from Boston Scientific, Cook Medical, Covidien/Medtronic. All other authors disclosed no financial relationships.
Funding Information:
DISCLOSURE: Dr Teshima received research support from Medtronic and Vantage Endoscopy. Dr Wang has consulted for Boston Scientific and undertaken research for Interscope and Fujinon. Dr Wallace has received research grants from Fujifilm, Medtronic, ChiroChem, Olympus, and Boston Scientific, has been a consultant for Ninepoint on behalf of Mayo Clinic and a general consultant for Cosmo Pharmaceuticals. Dr Haidry has undertaken research for Cook Medical, Pentax Europe, Covidien/Medtronic, Beamline Technologies, and C2 Therapeutics. Dr Koch has undertaken research for Cook medical and Interscope and has received speaker and consultancy fees from ErbeElektromedizin. Dr Ragunath has received educational and research grants from Cook Medical, consultancy fees from Olympus, consultancy fees and educational grants from Boston Scientific, and educational and research grants from Pentax. Dr Weusten has received financial support for research and speaker fees from Pentax Medical. Dr Schoon has received speaker and consultancy fees from Medtronic, Boston Scientific, and Olympus, and financial support for research from Fujifilm. Dr Bisschops has received speaker fees from Medtronic, Pentax, and Fujifilm, consultancy fees from Medtronic, Boston Scientific, Pentax, and Fujifilm, and financial support for research from Cook Medical, Medtronic, Pentax, and Fujifilm. Dr Bergman has received financial support for research from Covidien/Medtronic, Olympus Endoscopy, Cook Medical, Boston Scientific, Erbe Medical, C2 Therapeutic, and Ninepoint Medical, and consultancy fees from Boston Scientific, Cook Medical, Covidien/Medtronic. All other authors disclosed no financial relationships.
Publisher Copyright:
© 2020 American Society for Gastrointestinal Endoscopy
PY - 2020/8
Y1 - 2020/8
N2 - Background and Aims: Multiband mucosectomy (MBM) is a widely used technique for the treatment of Barrett's esophagus (BE). However, large multicenter studies enabling a generalizable estimation of the risk of serious adverse events, such as perforation and postprocedural bleeding, are lacking. The aim of this study was to estimate the rate of, and risk factors for, serious adverse events associated with MBM. Methods: In this retrospective analysis, consecutive patients who underwent MBM for treatment of BE in 14 tertiary referral centers in Europe, the United States, Canada, and Australia were included. Primary outcomes were perforation and postprocedural bleeding rate. Potential risk factors were identified by logistic regression. Results: Between 2001 and 2016, a total of 3827 MBM procedures were performed in 2447 patients (84% male, mean age 66 years, median BE length C2M4). Perforation occurred in 17 procedures (0.4%; 95% confidence interval [CI], 0.3-0.7), of which 15 could be treated endoscopically or conservatively. Female gender was an independent risk factor for perforation (odds ratio [OR], 2.77; 95% CI, 1.02-7.57; P =.05). Postprocedural bleeding occurred after 35 procedures (0.9%; 95% CI, 0.6-1.3). The number of resections (OR, 1.15; 95% CI, 1.06-1.25; P <.001) was significantly associated with postprocedural bleeding. Conclusion: The results of this study show that MBM for BE is safe with a low risk of serious adverse events. In addition, most of the adverse events could be managed endoscopically or conservatively. The number of resections was an independent risk factor for postprocedural bleeding.
AB - Background and Aims: Multiband mucosectomy (MBM) is a widely used technique for the treatment of Barrett's esophagus (BE). However, large multicenter studies enabling a generalizable estimation of the risk of serious adverse events, such as perforation and postprocedural bleeding, are lacking. The aim of this study was to estimate the rate of, and risk factors for, serious adverse events associated with MBM. Methods: In this retrospective analysis, consecutive patients who underwent MBM for treatment of BE in 14 tertiary referral centers in Europe, the United States, Canada, and Australia were included. Primary outcomes were perforation and postprocedural bleeding rate. Potential risk factors were identified by logistic regression. Results: Between 2001 and 2016, a total of 3827 MBM procedures were performed in 2447 patients (84% male, mean age 66 years, median BE length C2M4). Perforation occurred in 17 procedures (0.4%; 95% confidence interval [CI], 0.3-0.7), of which 15 could be treated endoscopically or conservatively. Female gender was an independent risk factor for perforation (odds ratio [OR], 2.77; 95% CI, 1.02-7.57; P =.05). Postprocedural bleeding occurred after 35 procedures (0.9%; 95% CI, 0.6-1.3). The number of resections (OR, 1.15; 95% CI, 1.06-1.25; P <.001) was significantly associated with postprocedural bleeding. Conclusion: The results of this study show that MBM for BE is safe with a low risk of serious adverse events. In addition, most of the adverse events could be managed endoscopically or conservatively. The number of resections was an independent risk factor for postprocedural bleeding.
UR - http://www.scopus.com/inward/record.url?scp=85087006509&partnerID=8YFLogxK
U2 - 10.1016/j.gie.2020.03.3842
DO - 10.1016/j.gie.2020.03.3842
M3 - Article
C2 - 32240684
AN - SCOPUS:85087006509
SN - 0016-5107
VL - 92
SP - 259-268.e2
JO - Gastrointestinal Endoscopy
JF - Gastrointestinal Endoscopy
IS - 2
ER -